Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8517259 | Neuropharmacology | 2018 | 51 Pages |
Abstract
showing the therapeutic effects of Berberine (BRB) in experimental DN. BRB inhibits mitochondrial complex I partially and thereby cause increased AMP/ATP ratio, which stimulates AMPK activity (Thr 172 phosphorylation). Phosphorylated AMPK produces several beneficial therapeutic effects in DN either by transcriptional regulation or by direct phosphorylation of several cellular targets. Its activation can also exert changes in NAD pool to stimulate SIRT1 activity. SIRT1 activation is also observed to produce similar metabolic and mitochondrial effects as that of AMPK.(AMPK: AMP activated protein kinase, mTOR: mammalian target of rapamycin, Nrf2: Nuclear factor (erythroid-derived 2)-like 2, NF-κB: Nuclear factor kappa B, PGC-1α: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha).246
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Veera Ganesh Yerra, Anil Kumar Kalvala, Bhoomika Sherkhane, Aparna Areti, Ashutosh Kumar,